Barak Palatchi

CEO of stebabiotech.com ⏪ Developing ImPACT© A novel, non-invasive oncology platform for hard-to-treat cancers

Barack Palatchi is the CEO of Steba Biotech, focusing on advancing a pioneering approach to treating solid tumors using the proprietary Oncology Platform, Padeliporfin ImPACT.

Steba is making significant advancements in the treatment of solid tumors, aiming to transform the landscape of cancer treatment by offering innovative solutions for patients with limited options.

The company is working on demonstrating the effectiveness of Padeliporfin ImPACT both as a standalone treatment and in combination with other modalities, such as immune modulators like checkpoint inhibitors.

Barak has a background in Geopolitics and National Security & Strategic Studies, with experience in various roles at reputable organizations including Novartis, Pfizer, Samsung Electronics, and the US Congress.

Under Barak's leadership, Steba Biotech is on a three-year mission to realize the full potential of Padeliporfin ImPACT, with the goal of delivering life-saving treatments and ensuring exceptional returns for investors.

For more information on the ImPACT technology and updates on Steba Biotech's progress, visit https://stebabiotech.com/.